ALVR Stock Price, AlloVir, Inc. Quote, Chart

Market Summary

USD0.76+0.01

Delayedas of 17 May 2024, 11:49 am

1.33%

ALVR Stock Price

View Fullscreen

ALVR RSI Chart

ALVR Valuation

Market Cap

86.3M

Price/Earnings (Trailing)

-0.48

EV/EBITDA

0

Price/Free Cashflow

-0.63

MarketCap/EBT

-0.46

ALVR Price/Sales (Trailing)

ALVR Profitability

Return on Equity

-149.07%

Return on Assets

-124.55%

Free Cashflow Yield

-158.5%

ALVR Fundamentals

ALVR Earnings

Earnings (TTM)

-179.5M

Earnings Growth (Yr)

26.43%

Earnings Growth (Qtr)

49.24%

Breaking Down ALVR Revenue

52 Week Range

0.746.12

(Low)(High)

Last 7 days

-8.5%

Last 30 days

1.4%

Last 90 days

7.1%

Trailing 12 Months

-81.9%

How does ALVR drawdown profile look like?

ALVR Financial Health

Current Ratio

18.48

ALVR Investor Care

Shares Dilution (1Y)

22.88%

Diluted EPS (TTM)

-1.66

Tracking the Latest Insider Buys and Sells of AlloVir, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	sinha vikas	sold	-3,945	0.796	-4,957	see remarks
May 03, 2024	hagen brett r	sold	-1,271	0.796	-1,597	chief accounting officer
May 03, 2024	brainard diana	sold	-8,151	0.796	-10,240	chief executive officer
May 03, 2024	miller edward	sold	-1,839	0.796	-2,311	general counsel
Apr 22, 2024	sinha vikas	sold	-1,392	0.75	-1,857	see remarks
Apr 22, 2024	hagen brett r	sold	-360	0.75	-480	chief accounting officer
Apr 22, 2024	miller edward	sold	-567	0.75	-757	general counsel
Apr 19, 2024	miller edward	sold	-469	0.7506	-626	general counsel
Apr 19, 2024	hagen brett r	sold	-355	0.7506	-473	chief accounting officer
Apr 19, 2024	sinha vikas	sold	-1,141	0.7506	-1,521	see remarks

Which funds bought or sold ALVR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-193,837	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-92.12	-9,000	1,000	-%
May 15, 2024	Voya Investment Management LLC	sold off	-100	-14,618	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-24.63	-432,570	2,221,380	-%
May 15, 2024	Graham Capital Management, L.P.	sold off	-100	-55,912	-	-%
May 15, 2024	MARSHALL WACE, LLP	added	12.47	53,085	273,853	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	20.14	60,098	239,942	-%
May 15, 2024	AMUNDI	unchanged	-	2,822	33,727	-%
May 15, 2024	683 Capital Management, LLC	sold off	-100	-129,557	-	-%
May 15, 2024	Redmile Group, LLC	unchanged	-	143,289	1,440,330	0.05%

Are Funds Buying or Selling ALVR?

Are funds buying ALVR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALVR

No. of Funds

Unveiling AlloVir, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	gilead sciences, inc.	14.6%	16,635,286	SC 13G/A
Feb 09, 2024	artal international s.c.a.	5.8%	6,597,167	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 01, 2024	ecor1 capital, llc	9.3%	10,655,366	SC 13G
Jan 09, 2024	wilson john robert	4.69%	5,355,877	SC 13G/A
Jan 09, 2024	wilson john robert	8.98%	5,562,954	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 08, 2021	fmr llc	-	0	SC 13G/A

Recent SEC filings of AlloVir, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 03, 2024	144	Notice of Insider Sale Intent
May 03, 2024	144	Notice of Insider Sale Intent
May 03, 2024	144	Notice of Insider Sale Intent
May 03, 2024	144	Notice of Insider Sale Intent
Apr 23, 2024	4	Insider Trading

Peers (Alternatives to AlloVir, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

AlloVir, Inc. News

Latest updates

AlloVir, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-24.5%	144	191	248	283	244	277	294	200	231	287	317	328	351	371	394	118	139
Current Assets	-24.6%	141	188	220	253	212	243	272	177	206	253	282	316	340	361	384	107	127
Cash Equivalents	-4.5%	86.00	90.00	96.00	197	116	106	124	71.00	100	202	243	225	169	123	142	78.00	61.00
Net PPE	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
Liabilities	-47.3%	24.00	45.00	53.00	54.00	51.00	53.00	40.00	42.00	39.00	61.00	49.00	25.00	21.00	18.00	20.00	16.00	18.00
Current Liabilities	-73.0%	8.00	28.00	33.00	31.00	25.00	24.00	21.00	22.00	19.00	38.00	24.00	21.00	16.00	12.00	14.00	9.00	9.00
Shareholder's Equity	-17.4%	120	146	195	229	194	225	253	158	192	225	267	302	330	353	374	-	-
Retained Earnings	-4.6%	-686	-656	-596	-552	-506	-465	-427	-385	-385	-297	-239	-193	-156	-125	-99.90	-76.29	-55.32
Additional Paid-In Capital	0.6%	807	802	792	782	701	691	681	544	533	522	507	496	486	478	474	5.00	4.00
Shares Outstanding	0.6%	115	114	114	114	93.00	93.00	71.00	64.00	64.00	64.00	63.00	62.00	-	-	-	-	-
Float	-	-	-	-	265	-	-	-	144	-	-	-	599	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	-44.4%	-44,380	-30,735	-34,476	-27,122	-32,118	-31,571	-35,127	-28,878	-46,476	-28,068	-36,437	-22,888	-18,926	-21,093	-18,057	-11,118	-10,543	-	-	-
Share Based Compensation	-49.6%	5,034	9,994	10,468	10,288	10,029	9,042	10,855	10,951	10,467	15,860	10,286	9,726	8,103	4,431	3,860	492	646	-	-	-
Cashflow From Investing	58.6%	40,000	25,218	-66,851	37,894	41,724	13,537	-38,557	-479	-54,979	-13,523	54,967	79,712	64,827	1,922	-210,263	25,005	13,839	-	-	-
Cashflow From Financing	-100.0%	-	11.00	-	-	-	292	126,425	-	-	65.00	-	-	-	-354	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALVR Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 12,173	$ 30,718
General and administrative	10,662	12,513
Restructuring costs	9,464
Total operating expenses	32,299	43,231
Loss from operations	(32,299)	(43,231)
Total other income (loss), net:
Interest income	1,246	1,325
Other income (loss), net	754	723
Net loss	$ (30,299)	$ (41,183)
Net loss per share - basic	$ (0.26)	$ (0.44)
Net loss per share - diluted	$ (0.26)	$ (0.44)
Weighted-average common shares outstanding - basic	114,690,726	93,303,672
Weighted-average common shares outstanding - diluted	114,690,726	93,303,672
Comprehensive loss:
Net Income (Loss)	$ (30,299)	$ (41,183)
Other comprehensive income (loss), net of tax:
Unrealized (loss) gain on available-for-sale securities	(76)	167
Total other comprehensive income (loss)	(76)	167
Comprehensive loss	$ (30,375)	$ (41,016)

ALVR Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 86,039	$ 90,121
Short-term investments	54,491	93,822
Interest receivable	181	206
Prepaid expenses and other current assets	771	3,486
Total current assets	141,482	187,635
Restricted cash	554	852
Other assets		122
Operating lease right-of-use assets	2,107	2,187
Total assets	144,143	190,796
Current liabilities:
Accounts payable	765	6,761
Accrued expenses	4,596	10,086
Operating lease liability, current	2,295	10,781
Total current liabilities	7,656	28,367
Operating lease liability, long term	16,047	16,648
Total liabilities	23,703	45,015
Stockholders’ equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.0001 par value: 300,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 114,881,765 and 114,153,538 shares issued at March 31, 2024 and December 31, 2023, respectively; and 114,881,765 and 114,148,991 shares outstanding at March 31, 2024 and December 31, 2023, respectively	11	11
Additional paid-in capital	807,059	802,025
Accumulated other comprehensive loss	(138)	(62)
Accumulated deficit	(686,492)	(656,193)
Total stockholders’ equity	120,440	145,781
Total liabilities and stockholders’ equity	$ 144,143	190,796
Related Party
Current liabilities:
Amount due to related party		$ 739

About AlloVir, Inc.

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

CEO	Dr. Diana M. Brainard M.D.
WEBSITE	allovir.com
INDUSTRY	Biotechnology
EMPLOYEES	113

AlloVir, Inc. Frequently Asked Questions

What is the ticker symbol for AlloVir, Inc.? What does ALVR stand for in stocks?

ALVR is the stock ticker symbol of AlloVir, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AlloVir, Inc. (ALVR)?

As of Thu May 16 2024, market cap of AlloVir, Inc. is 86.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALVR stock?

You can check ALVR's fair value in chart for subscribers.

What is the fair value of ALVR stock?

You can check ALVR's fair value in chart for subscribers. The fair value of AlloVir, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AlloVir, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALVR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AlloVir, Inc. a good stock to buy?

The fair value guage provides a quick view whether ALVR is over valued or under valued. Whether AlloVir, Inc. is cheap or expensive depends on the assumptions which impact AlloVir, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALVR.